Insiders of Genworth Financial, Inc. (NYSE:GNW) would have made a tidy sum after selling US$1.9m worth of stock at a high price

By
Simply Wall St
Published
May 18, 2022
NYSE:GNW
Source: Shutterstock

Even though Genworth Financial, Inc. (NYSE:GNW) stock gained 6.0% last week, insiders who sold US$1.9m worth of stock over the past year are probably better off. Selling at an average price of US$4.25, which is higher than the current price might have been the right call as holding on to stock would have meant their investment would be worth less now than it was at the time of sale.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

Check out our latest analysis for Genworth Financial

Genworth Financial Insider Transactions Over The Last Year

The President, Thomas McInerney, made the biggest insider sale in the last 12 months. That single transaction was for US$657k worth of shares at a price of US$4.38 each. So what is clear is that an insider saw fit to sell at around the current price of US$4.07. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

Over the last year we saw more insider selling of Genworth Financial shares, than buying. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
NYSE:GNW Insider Trading Volume May 18th 2022

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Genworth Financial Insiders Are Selling The Stock

The last quarter saw substantial insider selling of Genworth Financial shares. In total, President Thomas McInerney dumped US$626k worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.

Insider Ownership of Genworth Financial

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Insiders own 1.5% of Genworth Financial shares, worth about US$30m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About Genworth Financial Insiders?

An insider hasn't bought Genworth Financial stock in the last three months, but there was some selling. Zooming out, the longer term picture doesn't give us much comfort. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example, Genworth Financial has 2 warning signs (and 1 which can't be ignored) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.